Solventum Corporation (NYSE:SOLV) is Mayar Capital Ltd.'s 3rd Largest Position

Mayar Capital Ltd. boosted its position in Solventum Corporation (NYSE:SOLV - Free Report) by 187.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,990 shares of the company's stock after purchasing an additional 56,700 shares during the quarter. Solventum comprises 11.7% of Mayar Capital Ltd.'s investment portfolio, making the stock its 3rd biggest position. Mayar Capital Ltd. owned about 0.05% of Solventum worth $6,615,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of SOLV. Vanguard Group Inc. lifted its position in Solventum by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 16,266,893 shares of the company's stock valued at $1,074,591,000 after purchasing an additional 75,631 shares during the last quarter. Trian Fund Management L.P. lifted its position in Solventum by 18.8% during the fourth quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company's stock valued at $559,054,000 after purchasing an additional 1,336,564 shares during the last quarter. Geode Capital Management LLC lifted its position in Solventum by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 3,460,405 shares of the company's stock valued at $227,992,000 after purchasing an additional 112,686 shares during the last quarter. Norges Bank bought a new stake in Solventum during the fourth quarter valued at approximately $203,740,000. Finally, Invesco Ltd. boosted its stake in Solventum by 6.4% in the fourth quarter. Invesco Ltd. now owns 2,923,119 shares of the company's stock worth $193,101,000 after buying an additional 176,201 shares in the last quarter.

Solventum Trading Down 1.1%

SOLV traded down $0.80 during midday trading on Wednesday, reaching $72.88. 161,855 shares of the company's stock traded hands, compared to its average volume of 1,104,069. The firm has a fifty day moving average of $73.84 and a two-hundred day moving average of $72.56. The stock has a market capitalization of $12.61 billion, a price-to-earnings ratio of 33.71, a P/E/G ratio of 1.90 and a beta of 0.55. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.19 and a quick ratio of 0.85. Solventum Corporation has a 52 week low of $47.16 and a 52 week high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.34 EPS for the quarter, beating analysts' consensus estimates of $1.19 by $0.15. The business had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.02 billion. Solventum had a return on equity of 31.01% and a net margin of 4.55%. Solventum's quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.08 EPS. On average, equities analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on SOLV shares. KeyCorp started coverage on Solventum in a research note on Friday, June 6th. They issued a "sector weight" rating for the company. Piper Sandler raised Solventum from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $78.00 to $87.00 in a research note on Monday, May 19th. Morgan Stanley raised Solventum from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $80.00 to $103.00 in a research note on Tuesday. Finally, Argus raised Solventum from a "hold" rating to a "buy" rating and set a $90.00 target price for the company in a research note on Tuesday, July 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $84.38.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.